HER 2 status in invasive breast cancer: Immunohistochemistry, fluorescence in-situ hybridization and chromogenic in-situ hybridization | Zendy

Sridhar Epari | Zendy; HemlataS Shirsat | Zendy; Tanuja Shet | Zendy; Rajani Bagal | Zendy; Rohini Hawaldar | Zendy; SangeetaB Desai | Zendy

Open Access

HER 2 status in invasive breast cancer: Immunohistochemistry, fluorescence in-situ hybridization and chromogenic in-situ hybridization

Author(s) -

Sridhar Epari,

HemlataS Shirsat,

Tanuja Shet,

Rajani Bagal,

Rohini Hawaldar,

SangeetaB Desai

Publication year - 2012

Publication title -

indian journal of pathology and microbiology

Language(s) - English

Resource type - Journals

eISSN - 0974-5130

pISSN - 0377-4929

DOI - 10.4103/0377-4929.97855

Subject(s) - cish , chromogenic in situ hybridization , immunohistochemistry , fluorescence in situ hybridization , in situ hybridization , concordance , breast cancer , biology , pathology , cancer , medicine , oncology , microbiology and biotechnology , gene , genetics , gene expression , chromosome

HER2/neu gene status in breast cancers can be evaluated by targeting protein and gene - immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH). Recent studies have shown chromogenic in-situ hybridization (CISH) as a relatively cheaper alternative.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research